S. Yoon

Publications331
h-index42
Citations6,695
Highly Influential Citations297
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Bae
  • 283 Publications, 4,349 Citations
  • J. Choi
  • 255 Publications, 5,011 Citations
  • J. Jang
  • 211 Publications, 2,932 Citations
  • P. Sung
  • 76 Publications, 926 Citations
  • Publications
  • Influence
The etiology of hepatocellular carcinoma and consequences for treatment.
Most patients with hepatocellular carcinoma (HCC) have liver cirrhosis, which develops following long periods of chronic liver disease. Cirrhosis is characterized by a decrease in hepatocyte… Expand
  • 397
  • 24
  • PDF
Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis
In a systematic review and meta-analysis, Giovanni Musso and colleagues examine the association between non-alcoholic fatty liver disease and chronic kidney disease. Please see later in the article… Expand
  • 320
  • 23
  • PDF
The Wilms Tumor Suppressor WT1 Encodes a Transcriptional Activator of amphiregulin
WT1 encodes a zinc finger transcription factor implicated in kidney differentiation and tumorigenesis. In reporter assays, WT1 represses transcription from GC- and TC-rich promoters, but its… Expand
  • 312
  • 10
Comparative study between doxorubicin-eluting beads and conventional transarterial chemoembolization for treatment of hepatocellular carcinoma.
BACKGROUND & AIMS Transarterial chemoembolization (TACE) is a widely used treatment for hepatocellular carcinoma. In order to maximize its therapeutic efficacy, doxorubicin-loaded drug-eluting beads… Expand
  • 176
  • 10
A randomized controlled study of preemptive lamivudine in patients receiving transarterial chemo‐lipiodolization
Reactivation of hepatitis B virus (HBV) during chemotherapy is well documented. However, there are limited data on this complication in patients with hepatocellular carcinoma (HCC) undergoing… Expand
  • 168
  • 8
  • PDF
CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
CD133 is a cancer stem-cell (CSC) marker associated with radioresistance and chemoresistance in various cancers. In the present study, CD133-expressing liver cancer cells following radiation exposure… Expand
  • 149
  • 7
Serum C‐reactive protein is a useful biomarker for predicting outcomes after liver transplantation in patients with hepatocellular carcinoma
  • H. An, J. Jang, +6 authors E. Jung
  • Medicine
  • Liver transplantation : official publication of…
  • 1 December 2012
Liver transplantation (LT) is a curative modality for hepatocellular carcinoma (HCC), especially in patients with cirrhosis. However, there are still risks of recurrence. C‐reactive protein (CRP), an… Expand
  • 62
  • 7
Long-term effect of stereotactic body radiation therapy for primary hepatocellular carcinoma ineligible for local ablation therapy or surgical resection. Stereotactic radiotherapy for liver cancer
BackgroundWe evaluated the long-term effect of stereotactic body radiation therapy (SBRT) for primary small hepatocellular carcinoma (HCC) ineligible for local therapy or surgery.MethodsForty-two HCC… Expand
  • 213
  • 6
Additional Sex Comb-like (ASXL) Proteins 1 and 2 Play Opposite Roles in Adipogenesis via Reciprocal Regulation of Peroxisome Proliferator-activated Receptor γ*
Our previous studies have suggested that the mammalian additional sex comb-like 1 protein functions as a coactivator or repressor of retinoic acid receptors in a cell-specific manner. Here, we… Expand
  • 63
  • 6
Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis
BackgroundThe objectives of this retrospective study was to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT… Expand
  • 122
  • 5